Vycor Medical, Inc. (VYCO) Q3 Revenue Falls 19% to $414.9K
Vycor Medical, Inc. (VYCO) reported a 19% year-over-year decline in Q3 2026 revenue to $414.9K, with nine-month revenue down 11% to $1.3M. GAAP net losses were $161.4K for Q3 and $325.8K for the nine-month period, though prior-period net loss figures were not provided.
How this was made

The 30-second read
Why it matters
The earnings miss underscores ongoing revenue contraction, which may trigger short‑selling or defensive positioning by traders.
Market read
The earnings release provides new, material data for VYCO, but the small scale limits broader market impact.
What to watch
Potential pipeline of product approvals or undisclosed cost‑cutting measures not reflected in this brief release.
Background
Vycor Medical, Inc. is a small medical‑device company that filed its Q3 2026 earnings release on TradingView.
Ticker impact
Q3 2026 revenue fell 19% YoY to $414.9K and nine‑month revenue fell 11% to $1.3M, with GAAP net losses of $161.4K and $325.8K.
likely downward pressure as investors digest the shrinking top line and losses
The company posted a material revenue drop and larger net loss versus the prior period, a fresh earnings disclosure for a micro‑cap.
Market effects
Signals weakness in the niche medical‑device segment for small‑cap firms.
Limited to U.S. micro‑cap investors; no broader regional effect.
Minimal global relevance.
Counterpoint
If the company can secure new contracts or a strategic partnership, the stock may rebound despite the current decline.
Key entities
- companyVycor Medical, Inc.
Micro‑cap medical‑device firm reporting Q3 2026 results.
